Area of research
Infectious Diseases · Critical Care and Intensive Care Medicine
Research interest
are centered on clinical and translational research in healthcare associated infections including healthcare-related infections, candidemia, and Clostridium difficile infection. Expand All Collapse All
Recovery and Stability of Omadacycline 150-mg Crushed Tablets Dispersed in Food or Water and Administered via Nasogastric Tube.
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study
Clostridioides difficile is a bacterial priority pathogen.
Emerging <i>Clostridioides difficile</i> ribotypes have divergent metabolic phenotypes.
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.
The impact of ibezapolstat and other <i>Clostridioides difficile</i> infection-relevant antibiotics on the microbiome of humanized mice.
The microbiome-restorative potential of ibezapolstat for the treatment of <i>Clostridioides difficile</i> infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae.
Prebiotics Improve Blood Pressure Control by Modulating Gut Microbiome Composition and Function: A Systematic Review and Meta-Analysis.
Microbiome-Based Therapeutics for Salt-Sensitive Hypertension: A Scoping Review.
Defining Fulminant <i>Clostridioides difficile</i> Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion.
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.
A quantitative PCR to detect non-toxigenic <i>Clostridioides difficile</i>.
A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk.
Candidiasis epidemiology and outcomes including emergence of <i>Candida auris</i> from a large, Southern US metro area: a six-year evaluation.
Clostridioides difficile should be considered a bacterial priority pathogen.
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of <i>Clostridioides difficile</i>.
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers.
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications.
Fidaxomicin resistance in <i>Clostridioides difficile</i>: a systematic review and predictive modeling with RNA polymerase binding sites.
Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies.
Healthcare Resource Utilization and Discharge Readiness in Adult Hospitalized Patients With Candidemia or Invasive Candidiasis Who Received an Echinocandin: An Analysis of United States Hospitals.
Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Specific Ribotypes.
Estimating <i>Clostridioides difficile</i> infection-associated readmission rates: A systematic review and meta-analysis.
Microscopy methods for Clostridioides difficile.
Erratum to "Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies" [J. Chromatogr. B 1236 (2024) 124057].